Batu Biologics Receives FDA IND Clearance

7 November 2017

Batu Biologics Receives FDA Clearance for First Multi-Pronged Immunotherapy Targeting the Blood Vessels that Feed Cancer Company’s First-in-Class Drug, ValloVax, Acts by Educating Immune System to Starve Tumors Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, has received an Investigational New Drug (IND) approval from the U.S. … Continue reading "Batu Biologics Receives FDA IND Clearance"....

Read Full Article About Businesswire.com

Batu Chooses Unusual Path, Unusual Weapon

25 May 2017

Crowdfunding Part of Financial Strategy; Cancer Fight Aims to Cut Tumors’ Blood Supply When it comes to small and scrappy biotechs, Batu Biologics might take the cake. Led by a 25-year-old college dropout, Batu got its start with a $100,000 infusion of cash from a crowdfunding campaign the team launched online… the company has filed 29 … Continue reading "Batu Chooses Unusual Path, Unusual Weapon"....

Read Full Article About Businesswire.com

Batu Biologics Launches #starvethetumor Campaign

10 May 2017

Batu Biologics Launches #starvethetumor Crowdfunding Campaign for ValloVax Cancer Immunotherapy Company is hosting a press conference on May 11th, 2017 to discuss our strategy for ValloVax development Batu Biologics, an immuno-oncology company dedicated to studying blood vessel formation within tumors, announced today the launch of an equity crowdfunding campaign on EquityNet. Read the full article … Continue reading "Batu Biologics Launches #starvethetumor Campaign"....

Read Full Article About Businesswire.com

Batu Publishes Oncotarget Paper

3 March 2017

Batu Biologics Publishes Mechanistic Preclinical Data for ValloVax Company authors peer reviewed publication describing the mechanism of action of the ValloVax™ mediated immune response Batu Biologics, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today the publication of mechanistic data for the ValloVax platform in the current issue of Oncotarget. Read the full article … Continue reading "Batu Publishes Oncotarget Paper"....

Read Full Article About Businesswire.com

Batu Biologics recruits San Diego Biotech Investor to BOD

24 February 2017

Batu Biologics Welcomes Rancho Santa Fe Biotech Investor to Board of Directors Batu Biologics Seed Round Investor John Peck Jr. to join Board of Directors Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, announced today the appointment of John Peck Jr., to its Board of Directors. Read … Continue reading "Batu Biologics recruits San Diego Biotech Investor to BOD"....

Read Full Article About Businesswire.com

Batu announces formation of Clinical Advisory Board

21 December 2016

Batu Biologics Welcomes Three Visionary Leaders to Its Newly Formed Clinical Advisory Board CAB to oversee the clinical development of Batu Biologics’ tumor vasculature targeting immunotherapeutic, ValloVax™ Batu Biologics, a San Diego based immuno-oncology company focused on the development of its tumor angiogenesis targeting immune therapy, ValloVax™, announced today the formation of a Clinical Advisory … Continue reading "Batu announces formation of Clinical Advisory Board"....

Read Full Article About Businesswire.com

Batu Biologics Recruits Dr. Vijay Mahant to SAB

3 March 2016

Batu Biologics Recruits Diagnostics Expert to Oversee Precision-Medicine Company Arm Vijay Mahant, PhD, will lead efforts in the development of gene-guided precision medicine related to the ValloVax immune therapy Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, announced today the appointment of Vijay Mahant, PhD, to its … Continue reading "Batu Biologics Recruits Dr. Vijay Mahant to SAB"....

Read Full Article About Businesswire.com

Batu Biologics selected to present at Cavendish Global Forum

9 February 2016

Forum uniquely brings together leading family offices, their foundations and sovereign wealth fund representatives seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences Batu Biologics, an immuno-oncology company, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place February 15th to February 18th at the … Continue reading "Batu Biologics selected to present at Cavendish Global Forum"....

Read Full Article About Businesswire.com

Batu Biologics Issues Shareholder Letter

26 January 2016

Batu Biologics Issues Shareholder Update on Upcoming Milestones for 2016 Batu Biologics releases its year-end shareholder recapping the milestones accomplished in 2015 for the ValloVax platform and establishing company directives for 2016. Read the full article at businesswire.com....

Read Full Article About Businesswire.com

Dr. Thomas Ichim joins as full-time CSO

21 December 2015

Founder of Batu Biologics Expands Involvement as Chief Scientific Officer Thomas Ichim, PhD, will oversee the scientific development of the ValloVax therapeutic program Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, announced today the appointment of Thomas Ichim, PhD, to the position of Chief Scientific Officer. Read … Continue reading "Dr. Thomas Ichim joins as full-time CSO"....

Read Full Article About Businesswire.com
1 2 3 4 6